Innoviva, Inc. annual report, FY2012

Business context and reporting period

The supplied filing is Theravance, Inc.’s Form 10-K for the fiscal year ended December 31, 2012, with unaudited quarterly data. The request metadata names Innoviva, Inc.; the filing itself identifies the registrant as Theravance, Inc. It is an annual report, not a standalone quarterly filing.

Theravance was a biopharmaceutical research and development company with partnered respiratory programs (FF/VI, UMEC/VI and MABA), plus programs in infectious disease, CNS/pain and gastrointestinal disorders. GSK was its principal development partner. The financial statements received an unqualified audit opinion, and management and the auditor reported effective internal control over financial reporting.

Financial and operating metrics

Revenue and loss figures are in U.S. dollars; per-share amounts are also U.S. dollars. No operating margin or gross margin is presented in the supplied filing text. The company reported an accumulated deficit of $1.335 billion at year-end.

For fourth-quarter 2012, revenue was $5.8 million, operating loss was $30.0 million, net loss was $31.3 million and basic and diluted loss per share was $0.33. Fourth-quarter 2011 revenue was $5.4 million and net loss was $37.0 million.

At December 31, 2012, the balance sheet showed $172.5 million of convertible subordinated notes due 2015; the reported fair value was $194.1 million. In January 2013, the company issued $287.5 million of 2.125% convertible subordinated notes due 2023, receiving about $244.4 million net of issuance costs, and spent $36.8 million on capped-call transactions. This subsequent financing is not included in 2012 year-end cash or balance-sheet debt.

Material changes versus the prior comparable period

• 2012 revenue increased by $111.3 million, primarily because termination of the Astellas VIBATIV collaboration triggered recognition of $125.8 million of previously deferred revenue. The increase should not be read as a comparable rise in recurring product or royalty revenue.
• Net loss narrowed substantially, but the company remained loss-making. Research and development spending rose 14%, mainly from external services for TD-1211 and TD-9855 studies, higher employee costs and VIBATIV advisory-committee activity.
• Operating cash use increased by $39.7 million, primarily due to higher R&D activity and inventory purchases. Year-end cash and investments increased, mainly because GSK-affiliated investors provided $229.3 million net from 2012 stock purchases.
• Long-term liabilities fell to $183.6 million from $300.3 million, principally reflecting the reduction in deferred revenue following the Astellas termination; the 2015 notes remained outstanding.

Outlook, commentary, risks and unusual items

• Management expected 2013 operating expenses to increase from 2012 and stated that year-end cash, cash equivalents and marketable securities were expected to fund at least 12 months of operations under then-current plans and assumptions.
• FF/VI’s U.S. COPD application was under FDA review, with a May 12, 2013 action goal date and an advisory committee meeting scheduled for March 2013. UMEC/VI’s U.S. application was accepted, with a December 18, 2013 action goal date. Approval, labeling, efficacy and safety remained uncertain.
• Potential payments to GSK under the vilanterol collaboration could total up to $220 million, with up to $140 million estimated as potentially payable in 2013. These were contingent on product development and launches; no related liability was recognized at year-end 2012.
• VIBATIV faced critical supply shortages after manufacturing problems at its prior supplier. Theravance was transferring supply to Hospira, but regulatory approval was required before Hospira-made product could be sold. The company intended to reintroduce VIBATIV in the U.S. later in 2013 if a reliable supply could be secured. Its EU marketing authorization had been suspended.
• TD-1211 had positive Phase 2b topline results, but Theravance was reassessing its Phase 3 strategy in light of potentially changing FDA requirements. Management also noted that self-funding Phase 3 or building a U.S. VIBATIV sales organization could materially increase spending.
• Other notable items included Astellas’ termination of the VIBATIV agreement and Merck’s new collaboration, which generated $4.4 million of 2012 recognized revenue. The company reported no material legal proceedings.
• Key risks include regulatory or clinical setbacks, reliance on partners and single-source manufacturing, continued operating losses and financing needs, competition, intellectual-property challenges, and GSK’s significant ownership and governance rights.

Important facts for investors to verify

• Confirm the issuer and security identity: the supplied filing is for Theravance, Inc. (ticker THRX), notwithstanding the Innoviva metadata.
• Separate recurring collaboration, royalty and product economics from the $125.8 million one-time Astellas deferred-revenue recognition when assessing 2012 revenue.
• Check subsequent regulatory decisions, safety findings and commercial performance for FF/VI and UMEC/VI against the review dates disclosed in the filing.
• Verify whether Hospira supply was qualified and whether VIBATIV was reintroduced, including the financial impact of inventory recoverability and any further supply delays.
• Assess the impact of the January 2013 notes, capped calls, potential GSK milestone obligations and ongoing cash burn on liquidity, dilution and financing needs.